PharmaCyte Biotech, Inc. — Form 10-K
Filed July 29, 2026 · analyzed by the Periodic Agent
10-K
— Neutral
significance 8/100
What the filing says
PharmaCyte Biotech amended its bylaws six times between 2014 and July 2023. Key changes: (1) eliminated cumulative voting in director elections (Nov 2022); (2) reduced shareholder quorum from majority to one-third of voting power (Sept 2018); (3) shifted annual meeting scheduling to board discretion; (4) extended record-date determination rules for adjourned meetings (July 2023). No financial transactions, counterparties, or dollar amounts involved—purely governance amendments signed by CEOs Kenneth Waggoner and Joshua Silverman.
Why this rating
Bylaws are routine corporate governance. Changes are modest procedural refinements (voting mechanics, quorum thresholds) with no direct revenue, cost, or strategic impact. No material business consequence for $6.3M-cap company.
See more from July 29, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.